MAR 0 9 2006 W

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of

to respond to a collection of the	ormation unless it contains a valid OMB control number
	Complete If Known
Application Number	10/655861
Filing Date	September 5, 2003
First Named Inventor	Wang Yi
Art Unit	1644
Examiner Name	Vandervegt, Francois P.
Attorney Docket Number	ALXN-P01-102

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (il known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Senter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.' Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
PV	CA	Abe et al., "Contribution of Anaphylatoxin C5a to Late Airway Responses after Repeated Exposure of Antigen to Allergic Rats," The Journal of Immunology 167(8):4651-4660 (2001)	
	СВ	Krug et al., "Complement Factors C3a and C5a are Increased in Bronchoalveolar Lavage Fluid after Segmental Allergen Provocation in Subjects with Asthma," Am. J. Respir. Crit. Care Med. 164:1841-1843 (2001)	
	CC	Peng et al., "Role of C5 in the Development of Airway Inflammation, Airway Hyperresponsiveness, and Ongoing Airway Response," The Journal of Clinical Investigation 115(6):1590-1600 (2005)	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	/R Dierre Vandervegt/	Date	01/20/2007
	/F Pierre Vandervegt/	1-1	1 01/20/2007
Signature	<u> </u>	Considered	

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.

OFFE TRACEMENT

PTC/SB/08a/b (07-05)

Approved for use through 09/30/2006. OMB 0551-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

	Complete If Known					
Application Number	10/655,861	_				
Filing Oate	September 5, 2003	_				
First Named Inventor	Yi Wang					
Art Unit	1644	_				
Examiner Name	Vandervegt, Francois P.					
Attorney Docket Number	ALXN-P01-102					

Examiner	Cite	Document Number	Publication Date	***************************************	Pages, Columns, Lines, Where Relevant Passages or Relevant			
Initials*	No.1	No.'	No.'	No.'	No.'	No.' Number-Kind Code* (#known)	Applicant of Cited Document	Figures Appear
		L						

	FOREIGN PATENT DOCUMENTS					
Examiner Cite		Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	- 6
Initials*	No.'	Country Code ³ -Number ⁴ -Kind Code ³ (if known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	Ŀ
			·		l	L

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-latter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
PV	CD	Abrahamsen et al., "Differential Mediator Release from Basophils of Allergic and Non-allergic Asthmatic Patients after Stimulation with Anti-IgE and C5a," Clinical and Experimental Allergy 31:368-378 (2001)	
	CE	Akatsu et al., "Distribution of Rat C5a Anaphylatoxin Receptor," Microbiol. Immunol. 46(12):863-874 (2002)	
	CF	Bjornson et al., "Complement is Activated in the Upper Respiratory Tract During Influenza Virus Infection," Am. Rev. Respir. Dis. 143:1062-1066 (1991)	
	CG	Blease et al., "Chemokines and Their Role in Airway Hyper-reactivity," Respir. Res. 1:54-61 (2000)	
	СН	Boulet et al., "Airway Hyperresponsiveness, Inflammation, and Subepithelial Collagen Deposition in Recently Diagnosed vs. Long-standing Mild Asthma," American Journal of Respiratory and Critical Care Medicine 162:1308-1313 (2000)	
	CI	Chakir et al., "Airway Remodeling-associated Mediators in Moderate to Severe Asthma: Effect of Steroids on TGF-β, IL-11, IL-17, and Type I and Type III Collagen Expression," J. Allergy Clin. Immunol. 111:1293-1298 (2003)	
	CJ	Chenoweth et al., "Demonstration of Specific C5a Receptor on Intact Human Polymorphonuclear Leukocytes," Proc. Natl. Acad. Sci. USA 75(8):3943-3947 (1978)	
	СК	Chung, "Cytokines in Chronic Obstructive Pulmonary Disease," Eur. Respir. J. 18(34):50s-59s (2001)	
	CL	Cieslewicz et al., "The Late, but not Early, Asthmatic Response is Dependent on IL-5 and Correlates with Eosinophil Infiltration," J. Clin. Invest. 104:301-308 (1999)	
	СМ	Collard et al., "Complement Activation Following Oxidative Stress," Molecular Immunology 36:941-948 (1999)	
	CN	Czermak et al., "Complement, Cytokines, and Adhesion Molecule Expression in Inflammatory Reactions," Proceedings of the Association of American Physicians 110(5):306-312 (1998)	
	co	Desai et al., "Demonstration of C5 Cleaving Activity in Bronchoalveolar Fluids and Cells: A Mechanism of Acute and Chronic Alveolitis," Journal of Experimental Pathology 1(3):201-216 (1984)	
\bigvee	СР	Drouin et al, "Expression of the Complement Anaphylatoxin C3a and C5a Receptors on Bronchial Epithelial and Smooth Muscle Cells in Models of Sepsis and Asthma," The Journal of Immunology 166:2025-2032 (2001)	

Examiner	Date	
	15000	<u> </u>
Signature	Considered	
Conditione	Considered	<u> </u>

PTO/SB/08a/o (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	Substitute for form 1449A/B/PTO		Complete if Known		
				Application Number	10/655,861
INF	ORMATI	ON DISC	LOSURE	Filing Date	September 5, 2003
STA	STATEMENT BY APPLICANT			First Named Inventor	Yi Wang
				Art Unit	1644
	(Use as many sheets as necessary)			Examiner Name	Vandervegt, Francois P.
heet	2	of	2	Attorney Docket Number	ALXN-P01-102

PV	CQ	Frank, "Complement: A Brief Review," J. Allergy Clin. Immunol. 84(4,1):411-420 (1989)
	CR	Gerard et al., "Complement in Allergy and Asthma," Current Opinion in Immunology 14:705-708 (2002)
	CS	Glovsky et al., "Is Complement Activation a Factor in Bronchial Asthma?," Int. Arch. Allergy Immunol. 118:330-332 (1999)
	CT	Gönczi et al., "The Severity of Clinical Symptoms in Ragweed-allergic Patients is Related to the Extent of Ragweed-induced Complement Activation in their Sera," Allergy 51:1110-1114 (1997)
	CU	Holgate et al., "The Bronchial Epithelium as a Key Regulator of Airway Inflammation and Remodelling in Asthma," Clinical and Experimental Allergy 29:90-95 (1999)
	CV	Höpken et al., "Teh C5a Chemoattractant Receptor Mediates Mucosal Defence to Infection," Nature 383:86-89 (1996)
	cw	Irvin et al., "Airways Hyperreactivity and Inflammation Produced by Aerosolization of Human C5A des arg1-3," Am. Rev. Respir. Dis. 134:777-783 (1986)
	СХ	Jagels et al., "C3a and C5a Enhance Granulocyte Adhesion to Endothelial and Epithelial Cell Monolayers: Epithelial and Endothelial Priming is Required for C3a-induced Eosinophil Adhesion," Immunopharmacology 46:209-222 (2000)
	CY	Karp et al., "Identification of Complement Factor 5 as a Susceptibility Locus for Experimental Allergic Asthma," Nature Immunology 1(3):221-226 (2000)
	CZ	Kodani et al., "Intratracheal Administration of Anaphylatoxin C5a Potentiates Antigen-induced Pulmonary Reactions Through the Prolonged Production of Cysteinyl-leukotrienes," Immunopharmacology 49:263-274 (2000)
	CA1	Larsen et al., "A Differential Effect of C5a and C5a des Arg inthe Induction of Pulmonary Inflammation," Am. J. Pathol. 100:179-192 (1980)
	CB1	Maruo et al., "Generation of Anaphylatoxins Through Proteolytic Processing of C3 and C5 by House dust Mite Protease," J. Allergy Clin. Immunol. 100:253-260 (1997)
	CC1	Mattos et al., "Matrix Metalloproteinase-9 Expression in Asthma," Chest 122:1543-1552 (2002)
	CD1	Nagata et al., "Activation of Human Serum Complement with Allergens," J. Allergy Clin. Immunol.80:24-32 (1987)
	CE1	Nagy et al., "The Development of Asthma in Children Infected with Chlamydia pneumoniae is Dependent on the Modifying Effect of Mannose-binding Lectin," J. Allergy Clin. Immunol. 112(4):729-734 (2003)
	CF1	Robbins et al., "Complement Activiation by Cigarette Smoke," L254-L259 (1990)
	CG1	Taube et al., "Inhibition of Complement Activation Decreases Airway Inflammation and Hyperresponsiveness," Am. J. Respir. Crit. Car Med. 168:1333-1341 (2003)
	CH1	Teran et al., "Identification of Neutrophil Chemotactic Factors in Bronchoalveolar Lavage Fluid of Asthmatic Patients," Clinical and Experimental Allergy 27:396-405 (1997)
	CI1	Varsano et al., "Generation of Complement C3 and Expression of Cell Membrane Complement Inhibitory Proteins by Human Bronchial Epithelium Cell Line," Thorax 55:364-369 (2000)
	CJ1	Wang et al., "Amelioration of Lupus-like Autoimmune Disease in NZB/WF1 Mice after Treatment with a Blocking Monoclonal Antibody Specific for Complement Component C5," Proc. Natl. Acad. Sci. USA 93:8563-8568 (1996)
	CK1	Wang et al., "Anti-C5 Monoclonal Antibody Therapy Prevents Collagen-induced Arthritis and Ameliorates Established Disease," Proc. Natl. Acad. Sci. USA 92:8955-8959 (1995)
V	CL1	Wills-Karp et al., "Interleukin-13: Central Mediator of Allergic Asthma," Science 282:2258-2261 (1998)

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.

Examiner	/F Dierre Vanderwegt/	Date	01/20/2007
	/F Pierre Vandervegt/	Date	U1/2U/2UU/ I
Signature	,	Considered	,,
[Signature]		Considered	1

78 2004 2 U.S. DEPARTMENT OF COMMENCE PATENT AND TRADEMARK										ATTY. DOCKET NO. 102 US					SERIAL NO. 10/655,861			
ATEMPCE															•			
								SUR										
(Use s	ev	era	1	she	et	s i	£	nece	essary)	ΔΡΡ	LICANT							
										Wa	ng							
										FILING DATE September 5, 2003				-4	GROUP Art Un 1651 1644			
						- -					Ŭ.S. 1	PATENT DO	CUMEN	T				
XAMINER NITIALS			DOCUMENT DATE NUMBER						DATE	NAME			CLASSSUBCLASS					
PV		6	3	_		5 0	_1			Lai et al								
PV		6		5 :		2 4	Ė	03	/12/2002	Evans et	aı.							
			\pm			\perp	\pm	<u> </u>										
		Н	+	+	+	+	╁	-		<u> </u>			<u> </u>					
								1_					<u> </u>	I				
														FOREI	GN I	PATE	NT D	
	DOCUMENT NUMBER DATE					BER	DATE	COUNTRY CLASS			5		SUBCLASS YES NO					
PV		0 6 4 9 4 6					6	8	EP				-		-+	IES		
			Ţ	1											\blacksquare			
		╁	╁	-	_	H	-	\dashv	 						上			
		1							OTHER DO	CUMENTS (I	ncluding Aut	nor, Tit.	le, Da	te, I	Pert	inen	t Pa	
											nt immune com							
PV			j	inf	lam	nma	ti	on a	nd hyper: , 2001.	reactivity	. Am J Physoi	l Lung C	ell M	ol Ph	ysic	ol.		
		上	1															
		H	╁							<u>. </u>								
			Ţ															
											DATE CONSID							